论文信息 - Should NICE’s threshold range for cost per QALY be raised? Yes

Should NICE’s threshold range for cost per QALY be raised? Yes

NICE has recently raised the threshold for end of life drugs. Adrian Towse argues it should consider doing the same for other treatments, but James Raftery (doi:10.1136/bmj.b185) believes that the threshold is already too high

A. Towse

[1] M. Jones-Lee,et al. Modelling the monetary value of a QALY: a new approach based on UK data. , 2009, Health economics.

[2] M. Buxton,et al. Searching for cost effectiveness thresholds in the NHS. , 2009, Health policy.

[3] M. Sculpher,et al. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial. , 2008, Health technology assessment.

[4] S Bryan,et al. The use of economic evaluations in NHS decision-making: a review and empirical investigation. , 2008, Health technology assessment.

[5] Stephen A. Martin,et al. The Link Between Health Care Spending and Health Outcomes: Evidence from English Programme Budgeting Data , 2007 .

[6] Karl Claxton,et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence , 2007, Journal of health services research & policy.

[7] N. Devlin,et al. Cost-effectiveness Thresholds: Economic and Ethical Issues , 2002 .

[8] Michael E. Chernew,et al. Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.